3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PET-MRI nanoparticles imaging of blood–brain barrier damage and modulation after stroke reperfusion

      research-article
      f1 , f2 , f3 , f4 , f5 , f1 , f4 , f1 , f1 , f6 , f6 , f1 , f1 , f7 , f1 , f5 , f8 , f6 , f2 , f6 , f4 , f6 , f4 , f6 , f4 , f4 , f4 , f1 , f4 , f1 , f4 , f5 , f8 , f9 , f8 , f1
      Brain Communications
      Oxford University Press
      nanoparticles, stroke, blood–brain barrier, choroid plexus, ischaemia–reperfusion damage

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In an acute ischaemic stroke, understanding the dynamics of blood–brain barrier injury is of particular importance for the prevention of symptomatic haemorrhagic transformation. However, the available techniques assessing blood–brain barrier permeability are not quantitative and are little used in the context of acute reperfusion therapy. Nanoparticles cross the healthy or impaired blood–brain barrier through combined passive and active processes. Imaging and quantifying their transfer rate could better characterize blood–brain barrier damage and refine the delivery of neuroprotective agents. We previously developed an original endovascular stroke model of acute ischaemic stroke treated by mechanical thrombectomy followed by positron emission tomography-magnetic resonance imaging. Cerebral capillary permeability was quantified for two molecule sizes: small clinical gadolinium Gd-DOTA (<1 nm) and AGuIX ® nanoparticles (∼5 nm) used for brain theranostics. On dynamic contrast-enhanced magnetic resonance imaging, the baseline transfer constant K trans was 0.94 [0.48, 1.72] and 0.16 [0.08, 0.33] ×10 −3 min −1, respectively, in the normal brain parenchyma, consistent with their respective sizes, and 1.90 [1.23, 3.95] and 2.86 [1.39, 4.52] ×10 −3 min −1 in choroid plexus, confirming higher permeability than brain parenchyma. At early reperfusion, K trans for both Gd-DOTA and AGuIX ® nanoparticles was significantly higher within the ischaemic area compared to the contralateral hemisphere; 2.23 [1.17, 4.13] and 0.82 [0.46, 1.87] ×10 −3 min −1 for Gd-DOTA and AGuIX ® nanoparticles, respectively. With AGuIX ® nanoparticles, K trans also increased within the ischaemic growth areas, suggesting added value for AGuIX ®. Finally, K trans was significantly lower in both the lesion and the choroid plexus in a drug-treated group (ciclosporin A, n = 7) compared to placebo ( n = 5). K trans quantification with AGuIX ® nanoparticles can monitor early blood–brain barrier damage and treatment effect in ischaemic stroke after reperfusion.

          Abstract

          Blood–brain barrier damage is the next target for neuroprotection after stroke ischaemia–reperfusion. Debatisse et al. used PET-MRI nanoparticles imaging for its precise quantification. Both brain infarct and choroid plexus permeabilities were significantly increased 2 h after recanalization. Finally, they were both decreased by a single ciclosporin A injection.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Blood-brain barrier dysfunction and recovery after ischemic stroke.

          The blood-brain barrier (BBB) plays a vital role in regulating the trafficking of fluid, solutes and cells at the blood-brain interface and maintaining the homeostatic microenvironment of the CNS. Under pathological conditions, such as ischemic stroke, the BBB can be disrupted, followed by the extravasation of blood components into the brain and compromise of normal neuronal function. This article reviews recent advances in our knowledge of the mechanisms underlying BBB dysfunction and recovery after ischemic stroke. CNS cells in the neurovascular unit, as well as blood-borne peripheral cells constantly modulate the BBB and influence its breakdown and repair after ischemic stroke. The involvement of stroke risk factors and comorbid conditions further complicate the pathogenesis of neurovascular injury by predisposing the BBB to anatomical and functional changes that can exacerbate BBB dysfunction. Emphasis is also given to the process of long-term structural and functional restoration of the BBB after ischemic injury. With the development of novel research tools, future research on the BBB is likely to reveal promising potential therapeutic targets for protecting the BBB and improving patient outcome after ischemic stroke.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global brain inflammation in stroke

            Stroke, including acute ischaemic stroke and intracerebral haemorrhage, results in neuronal cell death and the release of factors such as damage-associated molecular patterns (DAMPs) that elicit localised inflammation in the injured brain region. Such focal brain inflammation aggravates secondary brain injury by exacerbating blood-brain barrier damage, microvascular failure, brain oedema, oxidative stress, and by directly inducing neuronal cell death. In addition to inflammation localised to the injured brain region, a growing body of evidence suggests that inflammatory responses after a stroke occur and persist throughout the entire brain. Global brain inflammation might continuously shape the evolving pathology after a stroke and affect the patients' long-term neurological outcome. Future efforts towards understanding the mechanisms governing the emergence of so-called global brain inflammation would facilitate modulation of this inflammation as a potential therapeutic strategy for stroke.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke.

              Brain endothelial cells form a paracellular and transcellular barrier to many blood-borne solutes via tight junctions (TJs) and scarce endocytotic vesicles. The blood-brain barrier (BBB) plays a pivotal role in the healthy and diseased CNS. BBB damage after ischemic stroke contributes to increased mortality, yet the contributions of paracellular and transcellular mechanisms to this process in vivo are unknown. We have created a transgenic mouse strain whose endothelial TJs are labeled with eGFP and have imaged dynamic TJ changes and fluorescent tracer leakage across the BBB in vivo, using two-photon microscopy in the t-MCAO stroke model. Although barrier function is impaired as early as 6 hr after stroke, TJs display profound structural defects only after 2 days. Conversely, the number of endothelial caveolae and transcytosis rate increase as early as 6 hr after stroke. Therefore, stepwise impairment of transcellular followed by paracellular barrier mechanisms accounts for the BBB deficits in stroke. Copyright © 2014 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Brain Commun
                Brain Commun
                braincomms
                Brain Communications
                Oxford University Press
                2632-1297
                2020
                11 November 2020
                11 November 2020
                : 2
                : 2
                : fcaa193
                Affiliations
                [f1 ] Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1 , 69000 Lyon, France
                [f2 ] Siemens-Healthcare SAS , Saint-Denis, France
                [f3 ] CREATIS, CNRS UMR-5220, INSERM U1206, Université Lyon 1, INSA Lyon Bât. Blaise Pascal , 7 Avenue Jean Capelle, Villeurbanne 69621, France
                [f4 ] Hospices Civils of Lyon , 69000 Lyon, France
                [f5 ] Cynbiose SAS , Marcy-L'Etoile, France
                [f6 ] CERMEP - Imagerie du Vivant , Lyon, France
                [f7 ] Laboratory of Experimental and Clinical Pharmacology, Faculty of Sciences, Lebanese University-Beirut , Lebanon
                [f8 ] Univ Lyon, Institut Lumière Matière, CNRS UMR5306 , Université Claude Bernard Lyon 1, 69000 Lyon, France
                [f9 ] Institut Universitaire de France (IUF) , France
                Author notes
                Correspondence to: Pr Emmanuelle Canet-Soulas, Laboratoire CarMeN, Université de Lyon, INSERM U.1060/Université Lyon1/INRA U. 1397/INSA Lyon/Hospices Civils Lyon, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, 69500 Bron, France E-mail: emmanuelle.canet@ 123456univ-lyon1.fr
                Author information
                http://orcid.org/0000-0001-6290-605X
                http://orcid.org/0000-0001-7691-9652
                http://orcid.org/0000-0001-6531-9176
                Article
                fcaa193
                10.1093/braincomms/fcaa193
                7716090
                33305265
                8db1e243-e7c4-4e2a-a19f-134ff9b8638f
                © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 August 2020
                : 2 October 2020
                : 9 October 2020
                Page count
                Pages: 14
                Funding
                Funded by: French National Research Agency (ANR);
                Award ID: ANR-15-CE17-0020
                Funded by: Neurodis Foundation and the Recherche Hospitalo-Universitaire en Santé (RHU) MARVELOUS;
                Award ID: ANR-16-RHUS-0009
                Funded by: Brain and Mental Health;
                Award ID: ANR-10-IBHU-0003
                Categories
                Original Article
                AcademicSubjects/MED00310
                AcademicSubjects/SCI01870

                nanoparticles,stroke,blood–brain barrier,choroid plexus,ischaemia–reperfusion damage

                Comments

                Comment on this article